Trial Profile
An observational national cohort study evaluating the safety and effectiveness of potent P2Y12 inhibitors ticagrelor and prasugrel compared to clopidogrel in East Asian patients with acute coronary syndromes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2018
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research